Sun BioPharma Inc (SNBP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sun BioPharma Inc (SNBP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8242
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sun BioPharma Inc (Sun BioPharma), formerly Cimarron Medical Inc is a biopharmaceutical company that develops disruptive therapeutics for treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101, SBP-102 and SBP-103. Its SBP-101 produces superior anti-tumor activity in human cancer cell lines and is used for the treatment of patients with pancreatic ductal adenocarcinoma. Sun BioPharma’s SBP-102 is used for the treatment of patients with pancreatitis. The company offers clinical trials and drug development services. It partners with institutions, universities, cancer centers and research centers for the development of drugs. Sun BioPharma is headquartered in Waconia, Minnesota, the US.

Sun BioPharma Inc (SNBP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sun BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Sun BioPharma Raises USD1.5 Million in Venture Financing 11
Sun BioPharma Raises USD2 Million in Venture Financing 12
Sun Biopharma Raises US$3 Million In Venture Financing 13
Sun BioPharma Raises US$2.32 Million In Venture Financing 14
Sun BioPharma Raises US$0.55 Million In Seed Financing 15
Merger 16
Cimarron Medical Merges with Sun BioPharma in Reverse Merger Transaction 16
Equity Offering 17
Sun BioPharma Raises USD0.8 Million in Private Placement of Shares and Securities 17
Sun Biopharma Files Registration Statement to Raise up to USD19.37 Million in Public Offering of Shares 18
Sun BioPharma Plans to Raise Funds through Public Offering of Shares 19
Sun BioPharma Raises Funds in Private Placement of Shares and Warrants 20
Sun BioPharma Raises USD0.2 in Private Placement of Shares and Warrants 21
Sun BioPharma Raises USD2 Million in Private Placement of Shares and Warrants 22
Sun Biopharma Raises USD0.4 Million in Private Placement of Shares up on Exercise of Warrants 23
Sun Biopharma Raises USD1.2 Million in Private Placement of Shares 24
Sun Biopharma Raises USD0.02 Million in Private Placement of Shares up on Exercise of Warrants 25
Debt Offering 26
Sun BioPharma Raises USD3 Million in Private Placement of 5% Notes Due 2018 26
Sun BioPharma Raises USD3.1 Million in Private Placement of 5% Notes Due 2018 27
Sun BioPharma Inc – Key Competitors 28
Sun BioPharma Inc – Key Employees 29
Sun BioPharma Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 13, 2018: Sun BioPharma Provides a Business Update and Files Report for Q2 2018 31
May 14, 2018: Sun BioPharma Reports Financial Report For Q1 2018 33
Mar 21, 2018: Sun BioPharma Provides Business Update and Files Annual Report for 2017 35
Nov 14, 2017: Sun BioPharma Files Form 10-Q for Third Quarter 2017 and Provides Business Update 37
Aug 10, 2017: Sun BioPharma reports financial results for the second quarter 2017 39
May 11, 2017: Sun BioPharma Reports First Quarter 2017 Results 40
Mar 30, 2017: Sun BioPharma Announces Financial Report of Year End December 2016 42
Mar 30, 2017: Sun BioPharma Q4 net loss increases 43
Product News 44
02/01/2017: The NIH Awards Sun BioPharma Grant to Study SBP-101 for the Treatment of Pancreatitis 44
Clinical Trials 45
Feb 22, 2018: Sun Biopharma Files United States Patent Protecting the Manufacturing Process for Its Lead Drug Candidate, SBP-101 45
Jan 29, 2018: Sun Biopharma Announces Initiation of First-Line Combination Study of Sbp-101 With Gemcitabine and Nab-Paclitaxel in Patients With Pancreatic Cancer 46
Oct 04, 2017: Sun BioPharma Achieves Significant Milestone with Successful Completion of Patient Enrollment in Phase 1a Dose Escalation Safety Study of SBP-101 for Patients with Pancreatic Cancer 47
Aug 10, 2017: Sun BioPharma Provides Clinical Update 49
Jun 05, 2017: Sun BioPharma Announces Completion of the Fifth Patient Cohort in the Dose Escalation Phase 1a Study of SBP-101 for Pancreatic Cancer 50
Mar 30, 2017: Sun BioPharma Provides Phase 1 Trial Update on SBP-101 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sun BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sun BioPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sun BioPharma Raises USD1.5 Million in Venture Financing 11
Sun BioPharma Raises USD2 Million in Venture Financing 12
Sun Biopharma Raises US$3 Million In Venture Financing 13
Sun BioPharma Raises US$2.32 Million In Venture Financing 14
Sun BioPharma Raises US$0.55 Million In Seed Financing 15
Cimarron Medical Merges with Sun BioPharma in Reverse Merger Transaction 16
Sun BioPharma Raises USD0.8 Million in Private Placement of Shares and Securities 17
Sun Biopharma Files Registration Statement to Raise up to USD19.37 Million in Public Offering of Shares 18
Sun BioPharma Plans to Raise Funds through Public Offering of Shares 19
Sun BioPharma Raises Funds in Private Placement of Shares and Warrants 20
Sun BioPharma Raises USD0.2 in Private Placement of Shares and Warrants 21
Sun BioPharma Raises USD2 Million in Private Placement of Shares and Warrants 22
Sun Biopharma Raises USD0.4 Million in Private Placement of Shares up on Exercise of Warrants 23
Sun Biopharma Raises USD1.2 Million in Private Placement of Shares 24
Sun Biopharma Raises USD0.02 Million in Private Placement of Shares up on Exercise of Warrants 25
Sun BioPharma Raises USD3 Million in Private Placement of 5% Notes Due 2018 26
Sun BioPharma Raises USD3.1 Million in Private Placement of 5% Notes Due 2018 27
Sun BioPharma Inc, Key Competitors 28
Sun BioPharma Inc, Key Employees 29
Sun BioPharma Inc, Subsidiaries 30

List of Figures
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sun BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Sun BioPharma Inc (SNBP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Renco Group SpA:企業の戦略的SWOT分析
    Renco Group SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Telenet Group Holding NV (TNET):企業の財務・戦略的SWOT分析
    Telenet Group Holding NV (TNET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Tompkins Financial Corp (TMP):企業の財務・戦略的SWOT分析
    Tompkins Financial Corp (TMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Alzheimer’s Drug Discovery Foundation:製薬・医療:M&Aディール及び事業提携情報
    Summary Alzheimer's Drug Discovery Foundation (ADDF), formerly Institute for the Study of Aging is a drug discovery foundation. The foundation offers funds for drug discovery and development research programs in the field of Alzheimer’s disease, related dementias and cognitive aging. It offers servi …
  • Iproteos SL:製薬・医療:M&Aディール及び事業提携情報
    Summary Iproteos SL (Iproteos) is a biotechnology company that develops therapeutic drugs for human diseases. The company develops drugs to treat various therapeutic indications such as cognitive impairment associated with schizophrenia, epilepsy, paediatric cancer, and others. It provides research …
  • Ascendis Pharma A/S (ASND):企業の財務・戦略的SWOT分析
    Summary Ascendis Pharma A/S (Ascendis) is a biopharmaceutical company that offers drug discovery and development services. The company’s pipeline products include transcon growth hormone, transcon PTH, transcon CNP, and transcon peptides. Ascendis conducts research and develops new drug candidates f …
  • Yakult Honsha Co., Ltd.:企業の戦略・SWOT・財務情報
    Yakult Honsha Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Yakult Honsha Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • NWF Group plc (NWF):企業の財務・戦略的SWOT分析
    Summary NWF Group Plc (NWF) is a consumer goods company that offers animal feedstuffs products. The company operates through feeds, food and fuel segments. It offers products such as fuel oil, dairy products, animal feeds and agricultural products. Its offers fuel, food and feed business solutions. …
  • Country Club Hospitality & Holidays Ltd.
    Country Club Hospitality & Holidays Ltd. - Strategy, SWOT and Corporate Finance Report Summary Country Club Hospitality & Holidays Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Alliance Pharma Plc (APH):製薬・医療:M&Aディール及び事業提携情報
    Summary Alliance Pharma Plc (Alliance) is a specialty pharmaceutical company. It focuses on acquisition, licensing, registration and marketing of pharmaceutical products. It promotes acquired and licensed prescription products across various therapeutic categories such as dermatology, central nervou …
  • Nephros Inc (NEPH)-医療機器分野:企業M&A・提携分析
    Summary Nephros Inc (Nephros) is medical device company that develops and markets filtration products. The company offers infection control filters, dialysis ultrafilters, and hemodia filtration systems. Its dialysis ultrafilters are intended to be used to filter water and bicarbonate concentrate us …
  • Merrimack Pharmaceuticals Inc (MACK):医療機器:M&Aディール及び事業提携情報
    Summary Merrimack Pharmaceuticals Inc (Merrimack) is a clinical stage biopharmaceutical company that develops and commercializes medicines for the treatment of various types of cancers. The company’s marketed portfolio consists of Onivyde (irinotecan liposome injection) that encases irinotecan (mark …
  • PFB Corp (PFB):企業の財務・戦略的SWOT分析
    Summary PFB Corp (PFB) is a diversified company. The company manufactures and distributes insulating building products and technologies. The company provides EPS product solutions such as insulspan structural insulating panel systems, rating system, insulated concrete forming system, timber framing …
  • TaiMed Biologics Inc (4147):製薬・医療:M&Aディール及び事業提携情報
    Summary TaiMed Biologics Inc (TMB) is a biotechnology company that provides novel medicines for the prevention and treatment of viral infectious diseases. The company provides pipeline products such as TMB-355, TMB-607 and TMB-571, among others. It offers TMB-355 which is a proprietary humanized ant …
  • HLS Therapeutics Inc (HLS):製薬・医療:M&Aディール及び事業提携情報
    Summary HLS Therapeutics Inc (HLS Therapeutics) is a pharmaceutical company that offers central nervous system and cardiovascular therapeutic products. The company's product includes clozaril, absorica, vascepa and trinomial. Its clozapine is a pharmaceutical product used in the treatment of schizop …
  • BowLeven plc (BLVN):企業の財務・戦略的SWOT分析
    Summary BowLeven Plc (BowLeven) is an independent oil and gas exploration and production company. The company’s business activities include acquisition, exploration, and development of oil and gas properties. It holds equity interests in offshore and onshore exploration acreage in Cameroon and Gabon …
  • McKesson Corporation:企業の戦略・SWOT・財務情報
    McKesson Corporation - Strategy, SWOT and Corporate Finance Report Summary McKesson Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Tokyo Electric Power Company Holdings Inc (9501):企業の財務・戦略的SWOT分析
    Tokyo Electric Power Company Holdings Inc (9501) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Enanta Pharmaceuticals Inc (ENTA):企業の財務・戦略的SWOT分析
    Summary Enanta Pharmaceuticals Inc (Enanta) is a biotechnology company that discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of …
  • ASFINAG:企業の戦略・SWOT・財務情報
    ASFINAG - Strategy, SWOT and Corporate Finance Report Summary ASFINAG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆